Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection

被引:24
作者
Coelho, EAF
Tavares, CAP
Lima, KD
Silva, CL
Rodrigues, JM
Fernandes, AP
机构
[1] Univ Fed Minas Gerais, Sch Pharm, BR-31270901 Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, COLTEC, Sector Clin Pathol, BR-31270901 Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Inst Biol Sci, BR-31270901 Belo Horizonte, MG, Brazil
[4] Univ Fed Sao Paulo, Sch Med, BR-1404900 Ribeirao Preto, SP, Brazil
[5] Nanocore Biotecnol Ltda, Incubadora Supera, BR-1404900 Ribeirao Preto, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
D O I
10.1007/s00436-005-0088-5
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Heat shock proteins (HSPs) are highly conserved among different organisms. A mycobacterial HSP65 DNA vaccine was previously shown to have prophylactic and immunotherapeutic effects against Mycobacterium tuberculosis infection in mice. Here, BALB/c mice were immunized with mycobacterial DNA-hsp65 or with DNA-hsp65 and trehalose dymicolate (TDM), both carried by biodegradable microspheres (MHSP/TDM), and challenged with Leishmania (Leishmania) major. MHSP/TDM conferred protection against L. major infection, as indicated by a significant reduction of edema and parasite loads in infected tissues. Although high levels of interferon-gamma and low levels of interleukin (IL)-4 and IL-10 were detected in mice immunized with DNA-hsp65 or MHSP/TDM, only animals immunized with MHSP/TDM displayed a consistent Th1 immune response, i.e., significantly higher levels of anti-soluble Leishmania antigen (SLA) immunoglobulin G (IgG)2a and low anti-SLA IgG1 antibodies. These findings indicate that encapsulated MHSP/TDM is more immunogenic than naked hsp65 DNA, and has great potential to improve vaccine effectiveness against leishmaniasis and tuberculosis.
引用
收藏
页码:568 / 575
页数:8
相关论文
共 50 条
[11]  
DENAGEL DC, 1993, CRIT REV IMMUNOL, V13, P71
[12]   Leishmaniasis - Public health aspects and control [J].
Desjeux, P .
CLINICS IN DERMATOLOGY, 1996, 14 (05) :417-423
[13]  
FERNANDES AP, 1997, REV INST MED TROP SP, V39, P70
[14]   Protection against Leishmania donovani infection by DNA vaccination:: increased DNA vaccination efficiency through inhibiting the cellular p53 response [J].
Ghosh, A ;
Labrecque, S ;
Matlashewski, G .
VACCINE, 2001, 19 (23-24) :3169-3178
[15]   LEISHMANIASES OF THE NEW-WORLD - CURRENT CONCEPTS AND IMPLICATIONS FOR FUTURE-RESEARCH [J].
GRIMALDI, G ;
TESH, RB .
CLINICAL MICROBIOLOGY REVIEWS, 1993, 6 (03) :230-250
[16]   DNA vaccines: a key for inducing long-term cellular immunity [J].
Gurunathan, S ;
Wu, CY ;
Freidag, BL ;
Seder, RA .
CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (04) :442-447
[17]   Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection [J].
Gurunathan, S ;
Prussin, C ;
Sacks, DL ;
Seder, RA .
NATURE MEDICINE, 1998, 4 (12) :1409-1415
[18]   Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection [J].
Jones, DE ;
Ackermann, MR ;
Wille, U ;
Hunter, CA ;
Scott, P .
INFECTION AND IMMUNITY, 2002, 70 (04) :2151-2158
[19]   HEAT-SHOCK PROTEINS AND THE IMMUNE-RESPONSE [J].
KAUFMANN, SHE .
IMMUNOLOGY TODAY, 1990, 11 (04) :129-136
[20]  
KAYE PM, 1991, J IMMUNOL, V146, P2763